PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 27, 2010New England Journal of Medicine4,514 citations

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

View Full Paper
EKEunice L. KwakUniversity of ToledoYBYung‐Jue BangSeoul National University
D. Ross Camidge
D. Ross CamidgeAstraZeneca (United Kingdom)

Key Points

Key points are not available for this paper at this time.

Abstract

The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kwak et al. (2010) studied this question.

synapsesocial.com/papers/69daa30b0f32475823a3d6e4https://doi.org/10.1056/nejmoa1006448
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK2009 · 1,894 citations
  2. 2A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry2010 · 426 citations
  3. 3Molecular Biology of Anaplastic Lymphoma Kinase–Positive Anaplastic Large-Cell Lymphoma2002 · 126 citations
  4. 4Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-023410662009 · 207 citations
  5. 5Oncogenic protein tyrosine kinases2004 · 138 citations